12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Company News  |  Deals

Oxford BioTherapeutics, Kyowa Hakko Kirin deal

Oxford BioTherapeutics received exclusive, worldwide rights from Kyowa's BioWa Inc. subsidiary to use its Potelligent technology to develop and...

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >